- Bruker Corp‘s preliminary revenue for the first quarter ranged between $795 million and $800 million, surpassing the estimated $757.4 million.
- The reported revenue growth was approximately 10% year-over-year, with an anticipated low-double digit growth when accounting for constant exchange rates.
- The non-GAAP organic revenue growth is expected to be in the low-single digit percentages for the first quarter.
- Bruker’s Scientific Instrument (BSI) segment is projected to achieve mid-single digit percentage organic revenue growth.
- There is a high-teens percentage decline in organic revenue expected for the BEST segment, when considering intercompany eliminations.
- Analyst recommendations on Bruker Corp include 8 buys, 6 holds, and 1 sell.
A look at Bruker Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Bruker Corp has a mixed outlook for the long term. The company scores moderately in value, growth, and momentum, indicating potential for steady performance and market appeal. However, its scores for dividend and resilience are lower, suggesting some areas of concern. Bruker Corporation, known for its life science systems and X-ray technology tools, may need to focus on enhancing its dividend offering and building resilience to withstand market fluctuations for sustained success in the future.
Bruker Corp‘s Smartkarma Smart Scores reflect a balanced position in key factors influencing its long-term prospects. With a solid foundation in value, growth, and momentum, the company shows promise for continued development and competitiveness in the market. However, improvements in dividend yield and resilience could further strengthen Bruker’s position and support its goals for sustained growth and profitability. As a leader in life science systems and advanced materials research tools, Bruker Corporation is well-positioned to capitalize on opportunities by addressing these areas of improvement.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
